In Brief: GSK Sales Drop; FTC Bans Firm From U.S. Market; FDA Warning Letters
This article was originally published in The Tan Sheet
Executive Summary
GSK consumer sales drop 4%; Canadian firm banned from weight loss market; basic labeling failures triggers FDA warning letter; claims make Puna Noni products drugs; FDA finds another tainted supplement; and study shows Herbalife is not pyramid scheme.
You may also be interested in...
Industry Suggests Increase In Spiked Supplements Reflects FDA Investment In Testing, Targeted Selection
The number of products marketed as supplements and identified as tainted in 2013 grew 136% from 2011 – the year after FDA announced it would take “swift and strong” enforcement action. Trends in recalls and public notifications likely reflect FDA’s investment in testing products, a strategy in need of updating, supplement industry trade groups say.
J&J To Power Ahead With 10 Launches In Four Years
Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further.
Bayer's Efforts To Pioneer Tumor-Agnostic Market In Europe Held Back
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: